193 related articles for article (PubMed ID: 37525669)
21. Selpercatinib in RET-fusion positive metastatic non-small cell lung cancer: achievements and gray areas.
Belluomini L; Avancini A; Pasqualin L; Insolda J; Sposito M; Menis J; Tregnago D; Trestini I; Ferrara MG; Bria E; Milella M; Pilotto S
Expert Rev Anticancer Ther; 2022 Aug; 22(8):785-794. PubMed ID: 35726802
[TBL] [Abstract][Full Text] [Related]
22. Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors.
Khatri U; Dayal N; Hu X; Larocque E; Naganna N; Shen T; Liu X; Holtsberg FW; Aman MJ; Sintim HO; Wu J
Mol Cancer Ther; 2023 Jun; 22(6):717-725. PubMed ID: 37070927
[TBL] [Abstract][Full Text] [Related]
23. RET Inhibitors in Non-Small-Cell Lung Cancer.
Cascetta P; Sforza V; Manzo A; Carillio G; Palumbo G; Esposito G; Montanino A; Costanzo R; Sandomenico C; De Cecio R; Piccirillo MC; La Manna C; Totaro G; Muto P; Picone C; Bianco R; Normanno N; Morabito A
Cancers (Basel); 2021 Sep; 13(17):. PubMed ID: 34503226
[TBL] [Abstract][Full Text] [Related]
24. Pralsetinib for RET Fusion-Positive Advanced Non-small-Cell Lung Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Al Khayat MNMT; Armstrong N; Howick J; O'Meara S; Posadzki P; Ryder S; Ahmadu C; Konings SRA; Postma MJ; Duffy S; Wolff RF; van Asselt ADI
Pharmacoeconomics; 2023 Apr; 41(4):353-361. PubMed ID: 36757608
[TBL] [Abstract][Full Text] [Related]
25. Use of on-therapy ctDNA monitoring in a patient with
Yeung V; Kim C; Kiedrowski LA; Liu SV; Reuss JE
Transl Lung Cancer Res; 2022 Jan; 11(1):111-116. PubMed ID: 35242632
[TBL] [Abstract][Full Text] [Related]
26. Selpercatinib: A Review in Advanced RET Fusion-Positive NSCLC.
Nie T; Syed YY
Target Oncol; 2023 Jan; 18(1):169-176. PubMed ID: 36422787
[TBL] [Abstract][Full Text] [Related]
27. The efficacy and safety of selective RET inhibitors in RET fusion-positive non-small cell lung cancer: a meta-analysis.
Ke JY; Huang S; Jing ZT; Duan MC
Invest New Drugs; 2023 Oct; 41(5):768-776. PubMed ID: 37603207
[TBL] [Abstract][Full Text] [Related]
28. RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.
Novello S; Califano R; Reinmuth N; Tamma A; Puri T
Oncologist; 2023 May; 28(5):402-413. PubMed ID: 36821595
[TBL] [Abstract][Full Text] [Related]
29. LIBRETTO-432, a phase III study of adjuvant selpercatinib or placebo in stage IB-IIIA
Tsuboi M; Goldman JW; Wu YL; Johnson ML; Paz-Ares L; Yang JC; Besse B; Su W; Chao BH; Drilon A
Future Oncol; 2022 Sep; 18(28):3133-3141. PubMed ID: 35950566
[TBL] [Abstract][Full Text] [Related]
30. RET rearrangements in non-small cell lung cancer: Evolving treatment landscape and future challenges.
Servetto A; Esposito D; Ferrara R; Signorelli D; Belli S; Napolitano F; Santaniello A; Ciciola P; Formisano L; Bianco R
Biochim Biophys Acta Rev Cancer; 2022 Nov; 1877(6):188810. PubMed ID: 36202311
[TBL] [Abstract][Full Text] [Related]
31.
Zhang T; Wang H; Cai Z; Zhang S; Jiang C
Front Oncol; 2023; 13():1078076. PubMed ID: 37139148
[TBL] [Abstract][Full Text] [Related]
32. Response to selpercatinib in a patient with
Arora A; Zaemes J; Ozdemirli M; Kim C
Front Oncol; 2023; 13():1134151. PubMed ID: 36998440
[TBL] [Abstract][Full Text] [Related]
33. Response to Pralsetinib Observed in Meningeal-Metastatic
Zhao Z; Su C; Xiu W; Wang W; Zeng S; Huang M; Gong Y; Lu Y; Zhang Y
JTO Clin Res Rep; 2022 Jun; 3(6):100343. PubMed ID: 35711719
[TBL] [Abstract][Full Text] [Related]
34. KIF5B/RET fusion gene in surgically-treated adenocarcinoma of the lung.
Yokota K; Sasaki H; Okuda K; Shimizu S; Shitara M; Hikosaka Y; Moriyama S; Yano M; Fujii Y
Oncol Rep; 2012 Oct; 28(4):1187-92. PubMed ID: 22797671
[TBL] [Abstract][Full Text] [Related]
35. Targeted therapy of RET fusion-positive non-small cell lung cancer.
Shen Z; Qiu B; Li L; Yang B; Li G
Front Oncol; 2022; 12():1033484. PubMed ID: 36582799
[TBL] [Abstract][Full Text] [Related]
36. RET fusions in solid tumors.
Li AY; McCusker MG; Russo A; Scilla KA; Gittens A; Arensmeyer K; Mehra R; Adamo V; Rolfo C
Cancer Treat Rev; 2019 Dec; 81():101911. PubMed ID: 31715421
[TBL] [Abstract][Full Text] [Related]
37. RET Solvent Front Mutations Mediate Acquired Resistance to Selective RET Inhibition in RET-Driven Malignancies.
Solomon BJ; Tan L; Lin JJ; Wong SQ; Hollizeck S; Ebata K; Tuch BB; Yoda S; Gainor JF; Sequist LV; Oxnard GR; Gautschi O; Drilon A; Subbiah V; Khoo C; Zhu EY; Nguyen M; Henry D; Condroski KR; Kolakowski GR; Gomez E; Ballard J; Metcalf AT; Blake JF; Dawson SJ; Blosser W; Stancato LF; Brandhuber BJ; Andrews S; Robinson BG; Rothenberg SM
J Thorac Oncol; 2020 Apr; 15(4):541-549. PubMed ID: 31988000
[TBL] [Abstract][Full Text] [Related]
38. Advances in the treatment of RET-fusion-positive lung cancer.
Pall G; Gautschi O
Lung Cancer; 2021 Jun; 156():136-139. PubMed ID: 33933276
[TBL] [Abstract][Full Text] [Related]
39. Salvage Therapy With Selpercatinib for
d'Arienzo PD; Cunningham N; O'Sullivan H; Grieco C; Patel V; Popat S
JTO Clin Res Rep; 2023 Dec; 4(12):100581. PubMed ID: 38034820
[TBL] [Abstract][Full Text] [Related]
40. Therapeutic Advances in the Management of Patients with Advanced RET Fusion-Positive Non-Small Cell Lung Cancer.
Sun F; McCoach CE
Curr Treat Options Oncol; 2021 Jun; 22(8):72. PubMed ID: 34165651
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
